This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Leveraging Multiple Data Sources to Maximize the Potential for Recruitment Success
Alzheimer’s Disease (AD) is the most common form of dementia, and accounts for 60% to 80% of dementia cases. In this progressive disease,dementia symptoms gradually worsen over a number of years. Memory loss is mild during early stages, but individuals with late-stageAlzheimer's lose the ability to carry on a conversation and respond to their environment. The greatest known risk factor is increasing age, and the majority of people with Alzheimer's are 65 and older. That said, up to 5% of people with the disease have early onset Alzheimer's, which often appears when someone is in their 40s or 50s1. Studies indicate that people aged 65 and older survive an average of four to eight years after diagnosis of Alzheimer’s disease, yet some live as long as 20 years or more, demonstrating the slow, insidious progression of the disease2.
To build and maintain gold-standard, next generation R&D intelligence tools, Sitetrove, Trialtrove, Pharmaprojects, and Trialpredict have been undergoing a major program of investment. In addition to the many new and exciting changes on the horizon, the robust and reliable Citeline tools that you use to inform your business decisions will formally join Informa’s Pharma Intelligence family of brands.